triple agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-21. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
=== Retail sale of sauces === In the spring of 2020, Chick-fil-A test-trialed the sale of two of their dipping sauces at some supermarkets in Florida, with all profits earmarked for a scholarship fund for the company's store-level employees. The trial was considered successful, and distribution was expanded nationwide by 2021. Two more sauces were added in 2023. In October 2022, the company trialed expansion of the program to include its salad dressings in the Cincinnati metropolitan area and in parts of Tennessee, and expanded nationwide in spring 2023. In January 2025, Chick-fil-A announced plans to centralize its lemonade production by moving it from its restaurant locations to a single, automated facility in Santa Clarita, California. This new plant is capable of processing between 30 and 35 truckloads of lemons daily, with each truckload containing 50,000 pounds of lemons.
==== Animal models ==== The safety of adjuvants are often tested using animal models. Model animals are given a dose of the adjuvant (sometimes comparable to real human/animal vaccines, sometimes higher) by injection, at a site that may or may not be analogous to real-life use. For example, aluminium adjuvants can kill motor neurons when subcutaneously injected at the scruff of a mouse's neck; oil–water suspensions such as pristane produces a precursor to lupus when given to mice by intraperitoneal injection; and arthritis-prone rat strains develop rheumatoid arthritis when injected with 0.2–0.3 mL squalene at the tail. All three examples above concern the classical "grandfathered" adjuvants: if a new adjuvant candidate shows these ill effects in animal testing, it would likely not be further developed, let alone becoming widely used. But more importantly, no effect similar to the above has been found in humans during the decades of their use (including among people genetically predisposed to autoimmunity), showing that animal models are not perfect models – nothing can be a perfect model of another thing, after all.
Oxycodone/naloxone, sold under the brand name Targin among others, is a combination pain medication available as modified-release tablets administered by mouth. The oxycodone component is an opioid and is responsible for the pain-relieving effects. Naloxone, an opioid antagonist, opposes the effects of opioids but is poorly absorbed into the blood stream when administered orally; therefore, most of the dose remains in the gastrointestinal tract. This local presence reduces opioid-induced constipation by preventing oxycodone from binding to gut opioid receptors, without diminishing overall analgesic efficacy compared to oxycodone alone. A 2008 study demonstrated a significant reduction in constipation. Oxycodone/naloxone was released in 2014 in the United States, in 2006 in Germany, and has been available in some other European countries since 2009. In the United Kingdom, the 10 mg oxycodone / 5 mg naloxone and 20 mg / 10 mg strengths were approved in December 2008, and the 40 mg / 20 mg and 5 mg / 10 mg strengths received approval in July 2019. Preliminary evidence suggests that oxycodone/naloxone may be an effective treatment for severe, refractory restless legs syndrome if first-line therapies have not been effective.
Sources: en.wikipedia.org
Through the early stages of the game, Combine Civil Protection units pursue Gordon Freeman, the player character, through City 17 after Gordon's presence is mistakenly revealed to Dr. Breen. Due to Gordon's actions in Half-Life and his subsequent disappearance, which earned him a legendary reputation, Dr. Breen sees Gordon as a significant threat. As Gordon flees the city, Civil Protection units raid the resistance base of Black Mesa East and capture resistance leader Eli Vance, who is transferred to holding facilities at Nova Prospekt. Gordon, along with Eli's daughter Alyx, breaks into the facility to rescue him, but Eli is teleported to the Combine Citadel by double agent Judith Mossman. The strike against Nova Prospekt prompts a revolution by the citizens of Earth and heavy street fighting takes place. In Episode One, the destruction of the teleporter has isolated Combine forces on Earth, and its primary reactor has begun to melt down. This forces Gordon and Alyx to journey back into the critically damaged Citadel to stabilize its reactor while the city's inhabitants are evacuated. The Combine forces, however, instead attempt to accelerate the meltdown in order to contact their native dimension for reinforcements. After Alyx acquires an encrypted copy of the message to be sent, Overwatch forces desperately attempt to stop the pair from escaping the city, spurred on by Combine Advisors. As the pair escape on a train at the end of the game, the Citadel detonates and destroys City 17.
Salicylic acid (SA) is a hormone with a structure related to benzoic acid and phenol. It was originally isolated from an extract of white willow bark (Salix alba) and is of great interest to human medicine, as it is the precursor of the painkiller aspirin. In plants, SA plays a critical role in the defense against biotrophic pathogens. In a similar manner to JA, SA can also become methylated. Like MeJA, methyl salicylate is volatile and can act as a long-distance signal to neighboring plants to warn of pathogen attack. In addition to its role in defense, SA is also involved in the response of plants to abiotic stress, particularly from drought, extreme temperatures, heavy metals, and osmotic stress. Salicylic acid (SA) serves as a key hormone in plant innate immunity, including resistance in both local and systemic tissue upon biotic attacks, hypersensitive responses, and cell death. Some of the SA influences on plants include seed germination, cell growth, respiration, stomatal closure, senescence-associated gene expression, responses to abiotic and biotic stresses, basal thermo tolerance and fruit yield. A possible role of salicylic acid in signaling disease resistance was first demonstrated by injecting leaves of resistant tobacco with SA. The result was that injecting SA stimulated pathogenesis related (PR) protein accumulation and enhanced resistance to tobacco mosaic virus (TMV) infection. Exposure to pathogens causes a cascade of reactions in the plant cells.
=== Hyperthermia === Hyperthermia is an elevation of body temperature over the temperature set point, due to either too much heat production or not enough heat loss. Hyperthermia is thus not considered fever. Hyperthermia should not be confused with hyperpyrexia (which is a very high fever). Clinically, it is important to distinguish between fever and hyperthermia as hyperthermia may quickly lead to death and does not respond to antipyretic medications. The distinction may however be difficult to make in an emergency setting, and is often established by identifying possible causes.
Sources: en.wikipedia.org
Brinckerhoff (1922), former CEO and chairman of Anaconda Copper, world's largest producer of copper Morris Schapiro (1923), investment banker, grandfather of painter Jacob Collins '86 and brother of art historian Meyer Schapiro '24 Lawrence Wien (1925), real estate magnate and philanthropist who owns the Empire State Building Francis Levien (1926), lawyer, director of Gulf and Western Industries, namesake of Levien Gymnasium Herbert Hutner (1928), private investment banker, attorney, and philanthropist; fourth husband of socialite Zsa Zsa Gabor Ivan Veit (1928), former executive vice president of The New York Times Nathan S. Ancell (1929), co-founder of furniture company Ethan Allen Ira D. Wallach (1929), head of Central National-Gottesman, the largest privately held marketer of paper and pulp products Benedict I. Lubell (1930), oilman, philanthropist Arthur Ross (1931), philanthropist, businessman; vice president of Central National-Gottesman; namesake of Arthur Ross Pinetum in Central Park Henry G. Walter Jr. (1931), businessman, former chairman and CEO of International Flavors & Fragrances and pioneer in aromatherapy Robert D. Lilley (1933), former president of AT&T 1972–1976 and the New Jersey Bell Telephone Company 1965–1970 Macrae Sykes (1933), investment banker, former chairman of the American Stock Exchange Robert David Lion Gardiner (1934), banker, landowner, 16th Lord of the manor of Gardiners Island, direct descendant of 17th-century English settler Lion Gardiner Arnold A. Saltzman (1936), businessman, diplomat, art collector, philanthropist George J.
Increased pressure also plays a roles in many diabetic foot ulcerations as changes due to the disease causes the foot to have limited joint mobility and creates pressure points on the bottom of the foot. Effective measures to treat this includes a surgical procedure called the gastrocnemius recession in which the calf muscle is lengthened to decrease the fulcrum created by this muscle and resulting in a decrease in plantar forefoot pressure.
The United States, having become the only global superpower, used that ideological victory to reinforce its leadership position in the new world order, proclaiming that "the United States and its allies are on the right side of history." This new world order is referred to as "liberal hegemony" in international relations theory. Using the peace dividend, the United States Armed Forces were able to cut much of its expenditure, but the level rose again to comparable heights after the September 11 attacks and the initiation of the war on terror in 2001. Accompanying NATO expansion, Ballistic Missile Defense (BMD) systems were installed in Eastern Europe. However, from a relatively-weak developing country, China appeared as a fledgling emerging superpower that would challenge the U.S. and liberal democracy, creating new potential for worldwide conflict. In response to the rise of China, the U.S. has strategically "rebalanced" to the Asia-Pacific region, but also began to retreat from international commitments in favor of its own interests. Starting from the 2020s onward, the perceived threat of global terrorism in the post-9/11 era has expanded beyond Middle Eastern jihadist groups, culminating in the United States and Canada designating several drug cartels and transnational criminal organizations as terrorist organizations in the context of narcoterrorism and the war on drugs. The 2020s also found the Monroe Doctrine once again playing a central role in US foreign policy.
== Victim == Buzhu's father emigrated to the Netherlands from Morocco in the 1950s and worked in a Dutch mine. His mother later rejoined his father and the couple settled in Utrecht. The father then opened a butcher shop in Amsterdam and provided financial stability to the family. After his father died, Buzhu went into organized crime alongside other Moroccans who had emigrated to the Netherlands. In order to hide his illicit wealth, Buzhu pretended his money was earned through real estate investment. His real source of income was smuggling large quantities of drugs from Morocco. In the 1990s, he was convicted by Dutch police of possession of illegal firearms and participating in torture. On 24 June 2015, a friend of Buzhu's went to the police in Driebergen claiming he found a tracking beacon underneath his vehicle. Buzhu also came forward and claimed that the case was related to the kidnapping of coffee shop owner in 2009. The police closed the case without a thorough investigation. A few days later, he returned to the police station and filed a complaint against Ridouan Taghi and his right-hand man Saïd Razzouki for death threats. Further investigations led Buzhu to identify several organized criminals in the Dutch drug trade, with his statements giving rise to the 26Koper investigation. In 2016 his friend Ranko Scekic and another friend were the victims of an attempted assassination in Utrecht by Taghi's hitmen for their allegiance with Buzhu. The assassination was eventually called off due to heavy police presence in the neighborhood.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.